Taysha Gene Therapies/$TSHA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Ticker
$TSHA
Sector
Primary listing
Employees
73
Headquarters
Website
TSHA Metrics
BasicAdvanced
$1.1B
-
-$0.34
1.03
-
Price and volume
Market cap
$1.1B
Beta
1.03
52-week high
$5.51
52-week low
$1.05
Average daily volume
9.1M
Financial strength
Current ratio
10.476
Quick ratio
10.385
Long term debt to equity
30.785
Total debt to equity
31.546
Interest coverage (TTM)
-1,399.04%
Profitability
EBITDA (TTM)
-100.98
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,583.66%
Operating margin (TTM)
-1,618.54%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-25.70%
Return on equity (TTM)
-64.93%
Valuation
Price to revenue (TTM)
184.81
Price to book
4.9
Price to tangible book (TTM)
4.9
Price to free cash flow (TTM)
-13.693
Free cash flow yield (TTM)
-7.30%
Free cash flow per share (TTM)
-0.286
Growth
Revenue change (TTM)
-36.36%
Earnings per share change (TTM)
247.68%
3-year earnings per share growth (CAGR)
-56.57%
What the Analysts think about TSHA
Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.
Bulls say / Bears say
The FDA has granted Breakthrough Therapy designation to TSHA-102 for Rett syndrome, which will significantly speed up its development and regulatory review process.
Taysha raised $230 million in a follow-on public offering in August 2025, fully exercising the underwriters’ options and strengthening its balance sheet.
As of June 30, 2025, Taysha had $312.8 million in cash and cash equivalents, providing funding into 2028 for the TSHA-102 pivotal trial.
Taysha reported a net loss of $26.9 million in Q2 2025 against revenue of $1.99 million, demonstrating a high cash burn rate and the risk of future equity dilution.
TSHA-102 remains Taysha’s only late-stage program, making the company's valuation heavily dependent on the outcome of the Phase 1/2 pivotal trial.
The REVEAL trial is a single-arm, open-label study lacking a control group, which could pose challenges for regulatory assessment of efficacy during BLA review.
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
TSHA Financial Performance
Revenues and expenses
TSHA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Taysha Gene Therapies stock?
Taysha Gene Therapies (TSHA) has a market cap of $1.1B as of November 07, 2025.
What is the P/E ratio for Taysha Gene Therapies stock?
The price to earnings (P/E) ratio for Taysha Gene Therapies (TSHA) stock is 0 as of November 07, 2025.
Does Taysha Gene Therapies stock pay dividends?
No, Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next Taysha Gene Therapies dividend payment date?
Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.